Nisa Investment Advisors’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $52K | Buy |
2,049
+186
| +10% | +$4.4K | ﹤0.01% | 1839 |
|
|
2026
Q1 | $42.1K | Sell |
1,863
-6
| -0.3% | -$133 | ﹤0.01% | 1737 |
|
|
2025
Q4 | $48.4K | Sell |
1,869
-425
| -19% | -$10.1K | ﹤0.01% | 1630 |
|
|
2025
Q3 | $59.1K | Buy |
2,294
+78
| +4% | +$1.92K | ﹤0.01% | 1587 |
|
|
2025
Q2 | $53K | Sell |
2,216
-1,100
| -33% | -$27.7K | ﹤0.01% | 1573 |
|
|
2025
Q1 | $82.4K | Buy |
3,316
+12
| +0.4% | +$287 | ﹤0.01% | 1449 |
|
|
2024
Q4 | $62.2K | Buy |
3,304
+2,749
| +495% | +$48.3K | ﹤0.01% | 1615 |
|
|
2024
Q3 | $8.35K | Sell |
555
-26
| -4% | -$445 | ﹤0.01% | 2127 |
|
|
2024
Q2 | $16.6K | Buy |
581
+46
| +9% | +$1.31K | ﹤0.01% | 2010 |
|
|
2024
Q1 | $15.6K | Buy |
535
+46
| +9% | +$1.41K | ﹤0.01% | 1954 |
|
|
2023
Q4 | $16.5K | Sell |
489
-1,512
| -76% | -$44.2K | ﹤0.01% | 1929 |
|
|
2023
Q3 | $61.4K | Buy |
2,001
+1,514
| +311% | +$54.6K | ﹤0.01% | 1664 |
|
|
2023
Q2 | $19.5K | Sell |
487
-449
| -48% | -$18.6K | ﹤0.01% | 2113 |
|
|
2023
Q1 | $38K | Sell |
936
-655
| -41% | -$26.1K | ﹤0.01% | 1800 |
|
|
2022
Q4 | $61K | Buy |
1,591
+9
| +0.6% | +$438 | ﹤0.01% | 1714 |
|
|
2022
Q3 | $82K | Sell |
1,582
-129
| -8% | -$7.17K | ﹤0.01% | 1571 |
|
|
2022
Q2 | $100K | Buy |
1,711
+124
| +8% | +$8.12K | ﹤0.01% | 1505 |
|
|
2022
Q1 | $121K | Sell |
1,587
-138
| -8% | -$9.2K | ﹤0.01% | 1555 |
|
|
2021
Q4 | $108K | Sell |
1,725
-3,846
| -69% | -$212K | ﹤0.01% | 1490 |
|
|
2021
Q3 | $312K | Buy |
5,571
+1,033
| +23% | +$59.5K | ﹤0.01% | 1263 |
|
|
2021
Q2 | $275K | Sell |
4,538
-1,400
| -24% | -$88.6K | ﹤0.01% | 1310 |
|
|
2021
Q1 | $416K | Hold |
5,938
| – | – | ﹤0.01% | 1219 |
|
|
2020
Q4 | $355K | Buy |
5,938
+3,763
| +173% | +$220K | ﹤0.01% | 1270 |
|
|
2020
Q3 | $131K | Sell |
2,175
-21,146
| -91% | -$1.23M | ﹤0.01% | 1454 |
|
|
2020
Q2 | $1.22M | Buy |
23,321
+15,531
| +199% | +$649K | 0.01% | 723 |
|
|
2020
Q1 | $261K | Buy |
7,790
+300
| +4% | +$12.5K | ﹤0.01% | 1120 |
|
|
2019
Q4 | $339K | Buy |
7,490
+300
| +4% | +$12.7K | ﹤0.01% | 1208 |
|
|
2019
Q3 | $274K | Sell |
7,190
-558
| -7% | -$22.3K | ﹤0.01% | 1250 |
|
|
2019
Q2 | $337K | Hold |
7,748
| – | – | ﹤0.01% | 1192 |
|
|
2019
Q1 | $295K | Buy |
7,748
+7,398
| +2,114% | +$289K | ﹤0.01% | 1205 |
|
|
2018
Q4 | $15K | Sell |
350
-55
| -14% | -$2.57K | ﹤0.01% | 1555 |
|
|
2018
Q3 | $20K | Hold |
405
| – | – | ﹤0.01% | 1556 |
|
|
2018
Q2 | $13K | Buy |
405
+230
| +131% | +$7.94K | ﹤0.01% | 1656 |
|
|
2018
Q1 | $5K | Buy |
+175
| New | +$6.23K | ﹤0.01% | 1796 |
|
|
2016
Q4 | – | Sell |
-400
| Closed | -$14K | – | 1887 |
|
|
2016
Q3 | $14K | Hold |
400
| – | – | ﹤0.01% | 1744 |
|
|
2016
Q2 | $13K | Hold |
400
| – | – | ﹤0.01% | 1746 |
|
|
2016
Q1 | $21K | Buy |
+400
| New | +$23.4K | ﹤0.01% | 1594 |
|
Other funds holding PCRX
DPCM
Nisa Investment Advisors's PCRX Position: Q2 2026 in Review
Nisa Investment Advisors increased its Pacira BioSciences (PCRX) stake by 10% in Q2 2026, buying an estimated $4.4K and bringing the position to 2,049 shares worth $52K. The position accounts for ﹤0.01% of the portfolio, ranked #1839.
Nisa Investment Advisors first reported a position in PCRX in Q1 2016 and has held it in 37 quarters since. The position peaked at $1.22M in Q2 2020. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.
- Nisa Investment Advisors held 2,049 shares of Pacira BioSciences worth $52K as of Q2 2026.
- Nisa Investment Advisors bought 186 Pacira BioSciences shares in Q2 2026, an estimated $4.4K.
- Pacira BioSciences made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #1839 holding.
- Nisa Investment Advisors first reported a position in Pacira BioSciences in Q1 2016 and has held it in 37 quarters since.
- Nisa Investment Advisors's Pacira BioSciences position peaked at $1.22M in Q2 2020.
- 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.
Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.